Loading stock data…
NOVO-B.CO
kr263.00+3.05 (+1.17%)
Market OpenUpdated 10:31 AM EDT
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Novo Nordisk A/S in the Healthcare sector is trading at $260.10. The stock is currently near its 52-week low of $224.25, remaining 17.5% below its 200-day moving average. Technical signals show neutral RSI of 68 and bullish MACD crossover, explaining why NOVO-B.CO maintains its current current market pressure. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 68) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Pricekr263.00
Potential Upside
179.8%
Whystock Fair Valuekr735.91
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus22 analysts
Hold
Mean targetkr307.67+17.0%
Rangekr175.00 – kr444.00
Fundamentals
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabet...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
kr1.11T
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
10.77
Beta
Defensive asset. Lower volatility than the S&P 500.
0.27
Div Yield
Strong income play. Yield provides a meaningful total return floor.
639.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
60.70%
Volume
Today's trading volume
2.72M
Recent News
Alnylam Pharmaceuticals (ALNY) Advances Diabetes Drug Into Phase 2 Trial
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 New Contenders for S&P 500 Index. On April 17, 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) provided an update on its experimental drug, ALN-4324. Currently in its Phase 2 clinical trial, the company’s experimental RNAi therapeutic drug aims at treating type 2 diabetes. The trial involves a triple-blind, […]
Eli Lilly and Company’s (LLY) Foundayo Gets Prescribed 3,707 Times in the US in Second Week of Launch, Reuters Reports
Eli Lilly and Company (NYSE:LLY) is one of the best low volatility stocks to invest in right now. On April 24, Reuters reported that, according to analysts citing IQVIA data, Eli Lilly and Company’s (NYSE:LLY) newly launched oral weight loss drug, branded as Foundayo, was prescribed 3,707 times in the United States in the second […]
BofA Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO)
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) is one of the 10 oversold small cap stocks to buy now. On April 21, BofA analyst Alec Stranahan reduced the price target on Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to $41 from $44, while maintaining a Buy rating on the stock. Stranahan highlighted that Agios intends to seek accelerated approval and has […]
A Look At Hims & Hers Health (HIMS) Valuation After Fresh GLP-1 Analyst Endorsement And Pharma Partnerships
Hims & Hers Health (HIMS) is back in focus after fresh analyst coverage spotlighted its Novo Nordisk partnership and broader GLP-1 weight loss expansion, along with direct collaborations with Eli Lilly and recent platform upgrades. See our latest analysis for Hims & Hers Health. The latest analyst coverage and GLP-1 announcements have come alongside sharp short term momentum, with a 1 month share price return of 46.64%, while the 3 year total shareholder return of 163.68% points to a longer...
Why Eli Lilly (LLY) Shares Are Trading Lower Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.6% in the afternoon session after disappointing weekly prescription numbers for its key weight-loss drugs sparked concerns about its competitive standing against rival Novo Nordisk.